30 Dec 2024


Trilegal advised Senores Pharmaceuticals Limited (the “Company”) as their legal advisor as to Indian law in connection with the initial public offering of equity shares by the Company. Senores Pharmaceuticals Limited is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic area and dosage forms.
The transaction was led by Capital Markets Partners Bhakta Patnaik and Brajendu Bhaskar and comprised Malika Grewal and Aditya Dsouza, Senior Associates; and Arsh Sinha, Pratyusha Dasgupta and Kavya Krishnaswamy, Associates.
About Trilegal:
Trilegal is one of India’s leading law firms, offering expertise across the full spectrum of corporate legal services. With offices in four key cities of India, Trilegal not only serves a significant domestic clientele but also caters to multinational corporations and international clients, leveraging its global market insights and cross-border transaction capabilities.
Trilegal has been recognised as M&A Firm of the Year by IFLR Asia-Pacific 2024; Best Overall Law Firms by India Business Law Journal (IBLJ) 2024; Innovative Lawyers Asia-Pacific by Financial Times (FT) 2024; Law Firm of the Year by Deal Volume by VCCircle Awards 2024; India Deal Firm of the Year by Asian Legal Business (ALB) India Law Awards 2023; Best Law Firms to Work by Vahura 2022; Firm of the year for Client Service Excellence by Asia Law Awards 2021.
For more information, please get in touch with Anoop Siddak Singh Tuli | Mob: +91-9535377422 | BD@trilegal.com
Under the rules of the Bar Council of India, Trilegal is prohibited from soliciting work or advertising in any form or manner. By accessing this website, www.trilegal.com, you acknowledge that:
We prioritize your privacy. Before proceeding, we encourage you to read our privacy policy, which outlines the below, and terms of use to understand how we handle your data:
For more information, please read our terms of use and our privacy policy.